791614-78-3

Upstream product

• 791614-79-4 7-bromo-3-hydroxy-4H-benzo[1,4]thiazine-2-carboxylic acid ethyl ester 
• 7440-66-6 zinc 
• 80945-86-4 6-bromo-2-chloro-benzothiazole 
• 141-78-6 ethyl acetate 
• 182499-80-5 2,2′-disulfanediylbis(4-bromoaniline) 
• 36239-09-5 ethyl chlorocarbonylacetate 
• 23451-95-8 2-amino-5-bromobenzenethiol 

Downstream Products

• 1221931-54-9 ethyl 2-(6-phenylbenzo[d]thiazol-2-yl)acetate 
• 1221931-30-1 C₂₇H₂₆N₂O₃S 
• 1221918-30-4 C₂₃H₁₈N₂O₃S 
• 1221931-32-3 C₂₇H₂₆N₂O₄S 
• 1221931-56-1 C₁₅H₁₀NO₂S^(1-)*Na⁽¹⁺⁾ 
• 1221922-49-1 C₂₁H₂₂N₂O₃S 
• 1221925-79-6 C₁₇H₁₄N₂O₃S 
• 1221918-45-1 C₁₉H₁₆N₄O₂S 
• 1221931-28-7 C₂₁H₂₁BrN₂O₃S 
• 1312435-63-4 C₂₃H₂₆N₄O₄S 
• 1312429-90-5 C₁₈H₁₃N₃O₃S 
• 1312429-89-2 C₂₂H₂₁N₃O₃S 
• 1312435-61-2 C₂₂H₂₃N₃O₄S 
• 1312429-95-0 C₂₂H₂₀N₄O₂S 

Relevant academic research and scientific papers

OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle,Z is —NR5—, —O— or —S—,R5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like,R1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like,R2 and R3 are each independently hydrogen, halogen, hydroxy or the like,R4 is a group represented by the formula: —(CR6R7)n-R8, wherein R6 and R7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, Rx is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like,m is an integer of 0 to 3.

ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R1R2)-C(=O)-NR3R4 and a group represented by the formula: -R5, a broken line represents the presence or the absence of a bond, Z is -NR6-, =N-, -O-, or -S-, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

Fused bicyclic-substituted amines as histamine-3 receptor ligands

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods for using such compounds and compositions.

Fused bicyclic-substituted amines as histamine-3 receptor ligands

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods for using such compounds and compositions.

Fused bicyclic-substituted amines as histamine-3 receptor ligands

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods for using such compounds and compositions.